NEW YORK (GenomeWeb) – Crown Bioscience has acquired Molecular Response's patient-derived xenograft (PDX) business for an undisclosed amount, the companies announced today. 

Crown is acquiring Molecular Response's existing PDX models and 8,000 viable human tumors for model development. The tumors are from Molecular Response's viable tumor bank containing more than 140,000 cryopreserved 100 percent US tumor samples. As part of the deal, Crown will be able to select and develop additional models from Molecular Response's tumor bank. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.